Introduction
Chronic myeloid leukaemia (CML) is defined by the presence of the bcr-abl fusion gene, which results in expression of a constitutively activated tyrosine kinase that is essential for the proliferative advantage of the neoplastic clone. [1] [2] [3] Imatinib mesylate (Glivec or Gleevec, Novartis Pharmaceuticals, Basel) is a small molecule inhibitor of bcr-abl, which has become the treatment of choice for chronic phase CML. Imatinib induces a complete cytogenetic response (CCR) in 475% of de novo chronic phase CML patients. 4 These responses appear to be sustained in the majority of cases, with resistance developing at a low rate, mainly due to the development of point mutations in the kinase domain of bcr-abl which abrogate imatinib binding. [5] [6] [7] [8] [9] The presence in the blood of the leukaemia-specific BCR-ABL mRNA makes it possible to monitor the progress of the disease and response to treatment by polymerase chain reaction (PCR) methods. We and others [10] [11] [12] [13] [14] [15] [16] [17] have previously reported our experience with highly sensitive quantitative PCR for quantification of BCR-ABL mRNA. These studies demonstrate that changes in peripheral blood quantitative PCR for BCR-ABL reliably indicate disease response or progression.
Real-time quantitative reverse transcriptase PCR (RQ-PCR) response appears to be an excellent predictor of long-term progression-free survival in imatinib-treated patients. In particular, the achievement of a major molecular response (MMR; X3-log reduction in BCR-ABL) by 12 months is associated with a very low risk of disease progression in longer-term followup 13, 18 and the rate of MMR increases over time, perhaps up to 70% of patients after 44 months (Goldman et al. Blood 2005; 106: Abstract No. 163). The rate of MMR at 12 months after starting imatinib for chronic phase CML may be dependent on dose. Approximately 40% of patients achieve MMR at a dose of 400 mg/day. Using a different definition of MMR, a single-centre historical comparison found an increased rate of MMR with at a dose of 800 mg daily, as compared to 400 mg daily. 13, 19 Bone marrow karyotyping has been the gold standard for response assessment in CML and forms the standard monitoring procedure in clinical practice and in most clinical trials. A major cytogenetic response (MCR) is defined as a reduction in percentage Philadelphia-positive cells (%Ph þ ) to o35%, while a CCR requires absence of the Ph rearrangement in all cells examined. Major cytogenetic response without CCR is referred to as a partial cytogenetic response (PCyR).
Cytogenetic analysis is necessary to identify the acquisition of clonal abnormalities in bone marrow cells. Philadelphiapositive cytogenetic clonal evolution may be associated with disease progression in CML and is one of the defining criteria of the accelerated phase. Where this finding is associated with clinical and morphological evidence of accelerated phase, the overall prognosis is inferior to chronic phase CML. 20, 21 However, in cases where accelerated phase is defined solely by clonal evolution, the outcome is heterogeneous and the rate of response to imatinib (with short follow-up) may to be similar to that of chronic phase. [22] [23] [24] The development of clonal cytogenetic abnormalities in Ph-negative cells has also been observed during imatinib treatment of CML. In the two largest studies, none of 55 patients with Ph-negative clonal abnormalities had clinical features of myelodysplasia. 25, 26 However, there have been reports of overt myelodysplasia in association with Ph-negative clonal abnormalities in imatinib-treated patients. [27] [28] [29] Bone marrow aspiration is an invasive procedure. It results in discomfort and inconvenience for patients and in rare cases, more serious complications. 30, 31 These considerations have led us to question the need for routine follow-up of all CML patients with bone marrow aspiration and karyotyping where reliable and sensitive RQ-PCR is available.
Our aim was to define in a large number of imatinib-treated chronic phase CML patients the circumstances and number of patients in which routine bone marrow cytogenetic analysis provided additional, clinically relevant information which would not have been detected by a strategy of RQ-PCR monitoring and selective bone marrow examination in response to a significant increase in BCR-ABL levels. Secondly, we aimed to assess the correlation between log-reduction in BCR-ABL by RQ-PCR and partial or complete cytogenetic response. And thirdly, we aimed to estimate the incidence of clonal cytogenetic abnormalities in Ph-negative cells in patients treated with imatinib.
Materials and methods

Patients
We performed a retrospective analysis of laboratory monitoring results from 183 CML patients treated with imatinib. All patients were in first chronic phase, but patients with morphological chronic phase in whom accelerated phase had been diagnosed solely on the basis of Ph-positive cytogenetic clonal evolution were also included. All patients had RQ-PCR monitoring performed at our laboratory. This included local patients as well as those from various centres around Australia and New Zealand enrolled in clinical trials with centralised RQ-PCR analysis. These trials were the Novartis-sponsored CSTI571 0106 (IRIS) study and the Australasian Leukaemia and Lymphoma Group CML6 study (TIDEL). The characteristics of the patient group and details of their treatment prior to commencing imatinib are summarised in Table 1 . Information on imatinib dosing was not available, but the initial intended dose of imatinib was either 400 or 600 mg daily in all patients.
Cytogenetic analysis
Cytogenetic analysis was performed by Australasian laboratories using standard cytogenetic procedures. 32 Where possible, a minimum of 20 cells were analysed. The median number of cells examined was 40, with less than 20 cells suitable for analysis in 6% of cases. Results from less than 20 cells were not excluded from the analysed data set. The karyotype was described in accordance with international standard nomenclature. 33 
RQ-PCR analysis
We analysed 828 peripheral blood RQ-PCR results with simultaneous bone marrow cytogenetic analysis. The RQ-PCR method for BCR-ABL used TaqMan fluorescent hybridisation probes. The bcr gene was quantified to control for differences in the RNA quality and reverse transcription efficiency. 10, 34 The results were reported as BCR-ABL/BCR%. The reproducibility of the assay was such that a greater than two-fold change could reliably be detected at the level of a 3-log reduction from the standardised baseline. 35 The sensitivity of the RQ-PCR test varies over time, dependent on intrinsic variability in the assay and on sample quality, indicated by quantification of the bcr control gene. The study was performed over a period of years in which the RQ-PCR assay sensitivity was improved by continual optimisation procedures and consequently this value varied significantly over the life of the study (laboratory quality control data not shown). In our laboratory, the critical value of 0.08% (3-log reduction or MMR) is validated for samples with at least 40 000 BCR transcripts.
Data analysis
All available bone marrow cytogenetic results were collated, together with the results of RQ-PCR analysis performed within 14 days of the bone marrow aspiration. The log-reduction in RQ-PCR analysis was calculated using a standardised baseline BCR-ABL/BCR value at presentation of 80%, as previously described. 13 For the purposes of data presentation, results from samples in which BCR-ABL was undetectable were arbitrarily assigned a log-reduction value lower than the lowest detected BCR-ABL/BCR ratio (see Figure 1) .
Analysis of the correlation between BCR-ABL/BCR ratio and %Ph þ was performed using the nonparametric Spearman rank correlation coefficient. Analysis of the difference between BCR-ABL/BCR ratios among cytogenetic response groups was performed using the Kruskal-Wallis one-way analysis of variance on ranks. All statistical analyses were performed using Sigma Stat software.
Results
Monitoring of CML patients treated with imatinib
Correlation between RQ-PCR and marrow cytogenetics. The Spearman correlation coefficient for the paired analysis of %Ph þ versus RQ-PCR (BCR-ABL/BCR ratio) was 0.765 (n ¼ 828; Po0.001). This value is lower than previously reported in our laboratory. 10 The difference is in part a reflection of the higher proportion of individuals in sustained CCR in the current study. In the vast majority of these patients, BCR-ABL was still detectable by RQ-PCR with levels varying by 100-fold. When the results with 0%Ph þ were excluded, the Spearman correlation coefficient was 0.876 (n ¼ 251; Po0.001), which is comparable to other reports. 14, 15, 36 The exclusion of analyses with less than 20 metaphases did not increase the correlation coefficient.
In order to examine the effect of duration of imatinib treatment on the correlation between RQ-PCR and karyotyping, we calculated the correlation for all Ph-positive samples collected in the first year (n ¼ 213) and after the first year (n ¼ 38). The Spearman correlation coefficients were 0.872 and 0.768, respectively. Allowing for the low number of patients not in CCR after 12 months, these values suggest that the correlation is not time-dependent.
Cytogenetic response according to log-reduction in BCR-ABL. We examined the relationship between logreduction in BCR-ABL/BCR ratio and cytogenetic response group (No MCR, PCyR or CCR) at any time point for which data were available. The results of this analysis are presented in Figure 1 . Although there was some overlap between groups, there was a significant difference in median BCR-ABL/BCR ratio between all three cytogenetic response groups (Po0.001).
In Table 2 the number of RQ-PCR results at each level of logreduction in BCR-ABL is shown, together with the percentage of these results corresponding to MCR or CCR. At any given time point, 99.6% of results with a one-log reduction or better (BCR-ABL/BCR ratio p8%) were from patients in MCR. All patients with a 2-log reduction or better (BCR-ABL/BCR ratio p0.8%) were in MCR and achievement of a 2-log reduction was also strongly associated with CCR (95.7%). These data are in keeping with our previous analysis in a smaller group of patients. 18 Discrepant results occurred at all time points, evenly spread throughout the duration of follow-up. There were three results from three patients with at least a one-log reduction in BCR-ABL/BCR ratio who were not in MCR. The BCR-ABL/BCR ratios were 2.3-6.7% with 39-65% Ph-positive cells. There were 23 results from 19 patients not in CCR, despite attainment of at least a 2-log reduction in BCR-ABL/BCR ratio. In this group, the median BCR-ABL/BCR ratio was 0.22% (10th-90th centiles 0.076-0.59%). The percentage of Ph-positive cells was 1.4-7.5% (median 3.3%, or 1/30 cells examined).
Detection of cytogenetic progression by RQ-PCR. We defined cytogenetic progression as any one of the following criteria: (1) an absolute increase of X20% Ph-positive cells; or (2) sustained loss of CCR (i.e. confirmed on a second subsequent cytogenetic study) or (3) Ph-positive clonal evolution. The first criterion was used in order to exclude cases where there was an increase in %Ph þ , which was due to minor variation related to the sensitivity and reproducibility of the test. Using the above definition, cytogenetic progression occurred in 24/183 patients (13%).
A significant increase in BCR-ABL/BCR ratio was defined as a greater than two-fold increase from the best response previously attained. Because of the increased coefficient of variation of the test at low levels, 35 the increased BCR-ABL/BCR ratio was also required to exceed an absolute value of 0.08% (i.e. greater than two-fold increase and loss of MMR).
Cytogenetic progression occurred with a simultaneous or preceding significant increase in BCR-ABL/BCR in 20 of 24 patients (83%). Further details on the four remaining patients are presented in Table 3 . Three of the four had a significant increase in BCR-ABL/BCR ratio within 3 months after cytogenetic progression, while the remaining patient (Patient 3, Table 3 ) proceeded directly to allogeneic stem cell transplantation.
The percentage of tests in which cytogenetic progression was detected in any single bone marrow cytogenetic analysis is presented in Table 4 , stratified according to the level of logreduction in BCR-ABL/BCR in the corresponding RQ-PCR analysis. It can be seen that the frequency of detection of cytogenetic progression diminishes with increasing depth of response to imatinib therapy, so that the yield of cytogenetic testing is lowest in patients with the best molecular response.
Major molecular response. There were 320 analyses from 95 patients with a MMR. There was a median of three analyses Table 2 Cytogenetic response according to log-reduction in BCR-ABL Results indicating cytogenetic progression indicated in bold. CE ¼ Ph-positive clonal evolution; Ph, Philadelphia.
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per patient (range 1-10) with 21 patients having only one result in MMR. Less than 1% of results from patients in MMR (n ¼ 3) had the Ph rearrangement detectable on karyotyping. All were at a level of p5% of metaphases examined and all three patients were in CCR at the subsequent cytogenetic analysis. One of these three patients was tested during a rapid fall in BCR-ABL/ BCR ratio and %Ph þ . The remaining two patients had each been in CCR on two previous occasions over a 6-month period, indicating that the finding of an occasional Ph-positive metaphase with stable low BCR-ABL/BCR ratio does not necessarily represent loss of CCR. All 90 results with BCR-ABL undetectable by RQ-PCR were from patients in CCR. Among patients who had previously achieved a MMR, there was only one case of loss of cytogenetic response during the available follow-up period. This occurred in a patient who had an MMR on only one occasion. This was followed by a significant increase in BCR-ABL/BCR and detection of a BCR-ABL point mutation (E255K) prior to loss of cytogenetic response. No patient developed a clinically significant Ph-positive cytogenetic abnormality while in MMR.
Clonal cytogenetic abnormalities in Ph-negative cells
Philadelphia-negative cells with clonal cytogenetic abnormalities were found in 9/183 patients (5%). See Table 5 for details. Using ISCN criteria for clonality, single cell abnormalities were not included. 33 In three cases the abnormality was loss of the Y chromosome, which is of doubtful clinical significance (see Discussion below). Three other patients had an abnormality, which was also present in the Ph-positive cells and was identified as constitutional and therefore not considered significant in this study.
Thus, 6/183 or 3.3% developed a potentially significant Phnegative cytogenetic abnormality. The median age for this group of six patients was 50 years (versus 51 years overall), with 50% males. The median interval between diagnosis and detection of the clonal cytogenetic abnormality was 431 days. The median interval from commencement of imatinib to detection of the clonal cytogenetic abnormality was 317 days. Imatinib was given as first-line treatment in four of the six patients (67%) versus 74% from the overall population.
Only one patient (0.5%) had evidence of myelodysplasia and cytopenia. This was a 59-year-old female who was initially treated with interferon-a/cytarabine for 9 months followed by crossover to imatinib for inadequate haematological response. Monosomy 7, trisomy 8, trisomy 11 and trisomy 12 were detected 17 months after commencement of imatinib when her CML was in CCR. Follow-up bone marrow biopsies showed multilineage dysplasia with subsequent transformation to Ph-negative acute myeloid leukaemia with the karyotype 47, XX, þ 11.
Discussion
Our data indicate that the strategy of RQ-PCR monitoring every 3 months with selective bone marrow cytogenetic analysis targetted on the basis of RQ-PCR results can provide all of the Table 4 Cytogenetic progression according to simultaneous measurement of log-reduction in BCR-ABL RQ-PCR monitoring of CML DM Ross et al information currently required for clinical decision-making in CML while significantly reducing the number of bone marrow biopsies performed. Firstly, the level of log-reduction in BCR-ABL/BCR by RQ-PCR is strongly correlated with cytogenetically defined MCR or CCR. Secondly, no patient in this study experienced cytogenetic progression after the first 12 months without an indication of risk from RQ-PCR results. And finally, no patient experienced cytogenetic progression while in MMR. Several authors have examined the correlation between the percentage of Ph-positive cells in the bone marrow and RQ-PCR for BCR-ABL in the peripheral blood. 10, 12, 14, 15, 17, 18, 36 Despite some methodological differences, there is generally good agreement between these studies with regard to the correlation between marrow cytogenetics and blood RQ-PCR. Similarly, all have shown a separation of the average values, but some overlap between the cytogenetic response groups -no MCR, PCyR and CCR. Lange et al. 15 formally analysed their data derived using RQ-PCR expressed as a BCR-ABL/GAPDH ratio and used a best-fit model to distinguish MCR and CCR. In the future, international standardisation of RQ-PCR methodology will facilitate studies to assess the accuracy of BCR-ABL logreduction by RQ-PCR as an indicator of MCR and CCR.
Achievement of MMR is a good prognostic marker, with excellent progression-free survival. 13, 18 For patients who have not achieved MMR, prognosis based on conventional cytogenetic response criteria continues to provide useful information. At present, we suggest that patients who have not yet achieved MMR defined by rigorous RQ-PCR methodology should continue to undergo bone marrow aspiration for cytogenetic analysis. An analysis of cytogenetic response at 3 and at 6 months showed that there was no difference in progression-free survival between those achieving MCR/CCR at 3 months and those achieving MCR/CCR at 6 months (Druker et al. Blood 2003; 102: Abstract No. 634). However, a cytogenetic response in the range 66-95% Ph-positive at 6 months (versus 3 months) better defined patients at a high risk of disease progression. Based also on the timing of our four cases in which cytogenetic progression occurred prior to an increase in BCR-ABL/BCR ratio, we suggest that cytogenetic analysis should be performed in all patients after 6 months of imatinib treatment.
The reason for cases of discrepancy between BCR-ABL/BCR ratio and bone marrow Ph-positive cells is unclear. Despite differences in cellular composition of the blood and bone marrow, BCR-ABL/BCR ratios in both tissues show good agreement, 15, 18 suggesting that this is not a significant cause of discrepancy. We have found examples of low-level Ph-positivity in patients with a stable molecular response, suggesting that the small sample size (often 20-30 cells), and a high coefficient of variation of karyotyping is one cause of discrepancy.
We postulate that the kinetics of cytogenetic and molecular response differ. Lange et al. 15 speculate that this difference relates to the selective detection in cytogenetic analysis of residual cells with increased mitotic capacity. This hypothesis implies that the level of BCR-ABL expression is not the sole determinant of mitotic capacity in Ph-positive cells. It is also possible that there is downregulation of BCR-ABL mRNA expression in Ph-positive cells exposed to imatinib and that this may reduce the BCR-ABL transcript level to a greater extent than could be achieved by a simple reduction in leukaemic cell numbers.
We found a low rate of development of clonal cytogenetic abnormalities in Ph-negative cells in our imatinib-treated patients (3%), which is comparable with published reports. 25, 26 Although the cumulative incidence of these abnormalities is as yet unclear, the rate of clinical myelodysplasia in our experience, and in the published literature appears very low. In keeping with published reports, we found no association between the quality of CML treatment response and the likelihood of developing Ph-negative clonal abnormalities.
Loss of a Y chromosome was a common Ph-negative clonal abnormality observed in our patients, as has been noted in other myeloid malignancies. 37, 38 As loss of the Y chromosome can be found in a significant proportion of older males in the absence of any clonal haematological disorder, the pathological significance of this finding is uncertain. 38 Trisomy 8 was the next most common clonal abnormality and has also been reported in a wide range of other myeloid disorders [39] [40] [41] [42] and in CML patients treated with interferon. 26, 40, 43, 44 It has been postulated that the emergence of trisomy 8 during regression of the CML clone may represent the re-emergence of polyclonal haematopoiesis in a patient with underlying constitutional mosaicism. 40 We also observed one case of loss of the X chromosome, which has similarly been described as an age-related abnormality 45, 46 or as a constitutional mosaicism. 47, 48 In our study, the long median interval to detection of the abnormality may suggest that the majority are true acquired abnormalities.
There was no pattern of RQ-PCR results which might indicate the development of Ph-negative clonal cytogenetic abnormalities in our patients, so bone marrow cytogenetic analysis remains the only means of detection. However, in the absence of cytopenia or morphological dysplasia, it is unlikely that the finding of a Ph-negative clonal abnormality would result in a significant change in patient management. Studies with longterm follow-up will be needed to improve our understanding of the prevalence, predisposing factors and natural history of these abnormalities.
In situations where an alternative treatment strategy would be considered (e.g. allogeneic transplantation in a younger patient), monitoring for cytogenetic abnormalities in Ph-negative bone marrow cells may be appropriate. However, for routine patient care there is currently insufficient evidence to mandate regular cytogenetic monitoring for this purpose.
The value of bone marrow examination for monitoring of CML is not confined to cytogenetics, as morphological analysis provides additional information. In the short-term, its value for monitoring of disease response appears limited, as patients who achieve a complete haematologic response may have a range of cytogenetic responses from no response to CCR. 49, 50 The utility of marrow morphology for longer-term follow-up of CML patients, particularly with regard to the development of secondary malignancy or myelodysplasia remains to be defined. In the one case where we observed myelodysplasia, dysplastic features and cytopenia were also apparent on examination of the peripheral blood.
It should be noted that the majority of patients in this study received imatinib therapy de novo in early chronic phase. There was no discernible difference between these patients and others in the observed patterns of RQ-PCR monitoring results or in Phnegative cytogenetic abnormalities. However, it may not be appropriate to extrapolate our conclusions to patients receiving second-line imatinib therapy.
In our experience, RQ-PCR for BCR-ABL enables accurate monitoring of the response to imatinib therapy and is a strong predictor of loss of response. We have sought to establish simple and clinically useful criteria to apply to the interpretation of RQ-PCR results. It is important to emphasise that, as this analysis was performed in a reference laboratory, it may not be possible to extrapolate our findings to populations monitored by routine clinical laboratories elsewhere. Reliable quantification of BCR-ABL at low levels of residual disease is critically dependent on rigorous quality control procedures. It is essential for laboratories that adopt our recommendations to ensure that a sample with no detectable BCR-ABL is not incorrectly categorised as indicating MMR. An undetectable BCR-ABL result is only equivalent to MMR if the control gene level of the sample indicates sensitivity sufficient to ensure that the result is below the level established for MMR in that laboratory. In the future, the development of standardised RQ-PCR methodology and reporting criteria will facilitate comparison between centres.
We recommend bone marrow cytogenetic analysis at 6 months for all CML patients treated de novo with imatinib. Thereafter, the probability of cytogenetic progression without a significant increase in BCR-ABL/BCR ratio is extremely low and RQ-PCR can be used to determine the need for bone marrow cytogenetic monitoring. For the increasing number of patients who achieve a MMR during imatinib treatment, it is highly unlikely that they will derive clinical benefit from regular cytogenetic monitoring.
